Key result
Biventricular assist device implantation resulted in comparable 6-month mortality compared to left ventricular assist device implantation in patients with postoperative right heart failure.
Why the study?
Does biventricular VAD implantation compared to LVAD with temporary RVAD or inotropes improve 6-month mortality in patients with end-stage heart failure and severe right ventricular dysfunction?
Cohort (n=173)
No
Does biventricular VAD implantation compared to LVAD with temporary RVAD or inotropes improve 6-month mortality in patients with end-stage heart failure and severe right ventricular dysfunction?
Answers are grounded in this paper and cite their sources.
In patients with end-stage heart failure and severe right ventricular dysfunction, 6-month mortality is high and comparable whether managed with a biventricular VAD or an LVAD with temporary RVAD or inotropes.
Right ventricular failure (RVF) exposes ventricular assist device (VAD) recipients to a high risk of death, but its management has not yet been standardized. We report three separate management strategies used for VAD recipients that present with RVF at a single center: 1) Thoratec paracorporeal biventricular VAD implantation, 2) left ventricular assist device (LVAD) implantation with temporary CentriMag right ventricular assist device (RVAD), and 3) LVAD combined with inotropic therapy. We retrospectively compared the preoperative data, the clinical outcomes, and the rates of adverse events in 84 biventricular assist device (BiVAD) recipients and 89 LVAD recipients presenting with postoperative RVF (57 were treated with a temporary RVAD and 32 were managed medically). Risk factors for death were analyzed. The BiVAD recipients were significantly younger, more critically ill at the time of device implantation, and required extracorporeal membrane oxygenation, an intraaortic balloon pump, mechanical ventilation, inotropes, or cardiopulmonary resuscitation significantly more often (at the time of device implant) than the LVAD recipients with RVF. The 6 month mortality was comparable in the two groups: 44 BiVAD patients (52%) and 38 LVAD patients (43%). Age, previous cardiac surgery, low platelet count, increased creatinine levels, the use of preoperative mechanical ventilation, and the need for a temporary RVAD were associated with 6 month mortality. The occurrence of RVF at the time of device implantation is a severe situation; it is associated with excess mortality, even if it is managed using a BiVAD or a LVAD with a temporary RVAD, probably because of the high preoperative risk profiles of the patients. In all cases, RVF must be managed quickly.
No takes yet. Share an insight, caveat, or question.
Aïssaoui et al. (2014) conducted a cohort in Severe Right Ventricular Dysfunction in End-Stage Heart Failure (n=173). Biventricular assist device (BiVAD) vs. Left ventricular assist device (LVAD) was evaluated on 6 month mortality. Biventricular assist device implantation resulted in comparable 6-month mortality compared to left ventricular assist device implantation in patients with postoperative right heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: